HOME >> MEDICINE >> NEWS
Work on cancer-killing compound nets FSU professor major grant

TALLAHASSEE, Fla.--Within a laboratory on the Florida State University campus, a chemist leads a team of researchers in a quest to develop synthetic versions of rare natural substances. If all goes well, the team's efforts could pay off in the form of the next generation of cancer-fighting drugs.

Such research often is a long, laborious process that can take years to generate results -- but is essential if breakthroughs in medicine, engineering and the sciences are to occur. In the FSU chemist's case, the state of Florida has acknowledged that the wait may well be worth it.

Gregory B. Dudley, an assistant professor in FSU's department of chemistry and biochemistry, recently was awarded a $450,000, three-year grant from the James & Esther King Biomedical Research Program, which is operated by the Florida Department of Health.

The program (www.floridabiomed.com) supports biomedical research on the prevention, diagnosis, treatments and cures for tobacco-related diseases, including cancer.

Dudley and his doctoral students are doing research on the synthesis of roseophilin, a naturally occurring compound produced by an obscure species of bacteria. Roseophilin (pronounced rose-ee-oh-FILL-in), which was first identified by Japanese researchers in 1992, is cytotoxic, meaning it kills cancer cells.

Public funding such as the King grant is essential if scientists are to continue to make progress in the ongoing battle against cancer and other diseases, Dudley said.

"The grant will allow us to engage in the kind of fundamental research that is needed to bring down the cost and increase the effectiveness of future pharmaceutical drugs," he said.

Dudley explained that the overall mission of his lab is to develop better access to synthetic versions of "biologically important" chemicals for which nature provides a limited supply. Typically, he said, he and his students choose a molecule that has shown interesting properties and
'"/>

Contact: Gregory B. Dudley
gdudley@chem.fsu.edu
850-644-2333
Florida State University
12-Oct-2005


Page: 1 2 3

Related medicine news :

1. Nanoparticles carry cancer-killing drugs into tumor cells
2. New oxidation methods streamline synthesis of important compounds
3. AMPAKINE compounds a new potential treatment for respiratory depression
4. Green tea compound suppresses factors causing cartilage, bone destruction in arthritis
5. Green tea compound may be a therapy for people with rheumatoid arthritis
6. Anti-dandruff compound may help fight epilepsy
7. Depression among retired NFL players: Rates mirror the general public, but pain compounds symptoms
8. Chromium 6: A killer compound with an improbable trigger
9. New compound shows promise in halting HIV spread
10. New imaging compound might see Alzheimers earlier
11. U of M researchers discover compounds to shrink tumors

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Work cancer killing compound nets FSU professor major grant

(Date:3/6/2015)... Protein identification is increasingly being ... science research including drug discovery, diagnostics, immunology and ... was valued at $1,569.00 million in 2014 and ... 10.63% to reach $2,600.28 million in 2019. , ... protein based on protein size, shape, sequence and ...
(Date:3/6/2015)... As healthcare providers create one ... from disparate systems, they are using OnBase by ... efficiency. Enterprise content management (ECM) solutions ... IT solutions, including electronic medical records (EMR), enterprise ... , The following organizations have recently integrated ...
(Date:3/6/2015)... March 06, 2015 Saving Moses, a ... the world is traveling to Angola, Africa March 7-14 ... their malnutrition program. , This will be the organizations ... Angola, demonstrating their commitment to the region’s population by ... team will engage with the mothers and babies of ...
(Date:3/6/2015)... 06, 2015 Follow us on ... pharmacokinetics of a drug refers to testing of absorption, ... an organism. When toxicity studies are clubbed together with ... ADME/Tox. Increasing focus on lowering costs and time during ... worldwide. The traditional drug development model uses toxicity and ...
(Date:3/6/2015)... March 06, 2015 “On Tap” takes the ... the grand stage, to the silver screen and to modern ... precision toe-tapping numbers and their famous eye-high kicks! Producers, directors ... rich history of tap dancing in this robust show, showcasing ... of the United States. , “On Tap” is proud ...
Breaking Medicine News(10 mins):Health News:Protein Identification Market worth $2,600.28 Million By 2019 - New Research Report by MarketsandMarkets 2Health News:Protein Identification Market worth $2,600.28 Million By 2019 - New Research Report by MarketsandMarkets 3Health News:Healthcare Providers Select OnBase by Hyland to Improve Patient Care and Streamline Administrative Departments 2Health News:Healthcare Providers Select OnBase by Hyland to Improve Patient Care and Streamline Administrative Departments 3Health News:Saving Moses Returns to Angola to Continue Giving Infants and Children a Chance to Live 2Health News:Growing Need to Reduce Drug Development Costs Drives the Global ADME-Toxicology Testing Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Growing Need to Reduce Drug Development Costs Drives the Global ADME-Toxicology Testing Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:The Legacy Dancers, a Dazzling Dance Troupe of Former Rockettes, Kick to New Heights in “On Tap: From Broadway to the Silver Screen” 2
(Date:3/6/2015)... , March 6, 2015  Palatin Technologies, Inc. (NYSE MKT: ... 27 th Annual ROTH Conference on Wednesday, March 11, ... held at the Ritz Carlton Laguna Niguel in ... Spana , Ph.D., President and Chief Executive Officer of Palatin ... programs. About Palatin Technologies, Inc. ...
(Date:3/6/2015)... , March 6, 2015   Hospira, Inc. ... Food and Drug Administration (FDA) on today,s FDA approval of ... . This is a watershed moment for improving patient access ... leading global provider of biosimilars, Hospira has seen first-hand the ... a proud participant in these early stages of the development ...
(Date:3/6/2015)... March 6, 2015  Aethlon Medical, Inc. (OTCQB:AEMD), the ... diseases and cancer, today announced that James A. ... present a corporate overview at the 27th Annual ROTH ... time.  Aethlon was previously scheduled to present at 5:30 ... will be held at The Ritz-Carlton Hotel in ...
Breaking Medicine Technology:Hospira Statement on FDA Approval of the First Biosimilar in the United States 2Hospira Statement on FDA Approval of the First Biosimilar in the United States 3Update - Changed Time for Aethlon Medical Presentation at the 27th Annual ROTH Conference 2
Cached News: